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Abstract
Significant correlations between the response to induction chemotherapy and success
of subsequent radiotherapy have been reported and suggest that the response to
induction chemotherapy is able to predict a response to radiotherapy. Therefore,
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induction chemotherapy may be used to tailor the treatment plan to the individual
patient with head and neck cancer: following the planned subsequent (chemo)radia-
tion schedule, planning a radiation dose boost, or reassessing the modality of
treatment (eg, upfront surgery). Findings from reported trials suggest room for
improvement in clinical response assessment after induction chemotherapy, but an
optimal method has yet to be identified. Historically, indices of treatment efficacy in
solid tumors have been based solely on systematic assessment of tumor size. How-
ever, functional imaging (eg, fluorodeoxyglucose-positron emission tomography
(FDG-PET) potentially provides an earlier indication of response to treatment than
conventional imaging techniques. More advanced imaging techniques are still in an
exploratory phase and are not ready for use in clinical practice.
KEYWORD S
fluorodeoxyglucose-positron emission tomography (FDG-PET), head and neck squamous cell carcinoma,
induction chemotherapy, response assessment
1 | INTRODUCTION
The achievement of complete tumor regressions after sys-
temic chemotherapy has been a hallmark of progress in the
medical management of solid malignancies. Before the early
1970s, the role of chemotherapy for patients with head and
neck cancer was largely limited to palliation of incurable dis-
ease. The observations of frequent and significant tumor
regressions after chemotherapy alone in previously untreated
patients led to the introduction of chemotherapy before sur-
gery or radiation in potentially curable patients in expectation
of tumor responses that might permit a reduction in conven-
tional treatment modalities and provide the rationale for sub-
sequent use of chemotherapy as an adjuvant after treatment.1
Small studies of chemotherapy alone for laryngeal cancer
have reported high rates of complete and durable responses,
but the evidence level for chemotherapy alone is low.2,3
Thus, the early development of chemotherapy regimens for
head and neck cancer uniquely focused on the use of sys-
temic chemotherapy as induction treatment before local treat-
ment modalities. Since that time, the use of induction
chemotherapy in the management of locally advanced head
and neck squamous cell carcinoma (HNSCC) has grown.
Understanding the effects of induction chemotherapy on the
biology of the tumor before delivery of definitive treatment
(ie, [chemo]radiation or surgery) is paramount to provide as
much information as possible in order to tailor the treatment
plan to the individual patient: following the planned subse-
quent (chemo)radiation schedule, planning a radiation dose
boost or reassessing the modality of treatment.
Induction chemotherapy, also known as neoadjuvant
chemotherapy, has been investigated as a strategy to shrink or
downstage locoregionally advanced head and neck cancers,
increase organ preservation rates, and/or reduce the risk of
locoregional and/or distant recurrences.4 The largest
meta-analysis (Meta-Analyses of Chemotherapy in Head and
Neck Cancer) studying the effect of chemotherapy (adjuvant,
neoadjuvant, or concomitant) on overall and event-free sur-
vival included 87 trials and 16,485 patients. Induction chemo-
therapy reduced the risk of distant metastases with a hazard
ratio of 0.73.5 A more recent meta-analysis of 14 trials and
2099 patients found no significant difference in overall sur-
vival, disease-free survival, or locoregional recurrence
between previously untreated patients and patients with
resectable nonmetastatic HNSCC treated with induction
chemotherapy followed by locoregional treatment (surgery
and/or radiotherapy with or without concomitant chemother-
apy) compared with those with locoregional treatment only.6
This discrepancy is difficult to explain, but may possibly be
due to a difference in primary tumor sites and stages between
these different meta-analyses.7 Significant correlations
between the response to induction chemotherapy and success
of subsequent radiotherapy have been reported and suggest
that the response to induction chemotherapy is able to predict
a response to radiotherapy.8–12 It has been consistently dem-
onstrated in nearly every trial of induction chemotherapy that
the survival of responding patients is superior to that of non-
responding patients, suggesting that chemotherapy response
is one of the strongest and most reliable prognostic indicators.
The differing clinical responses to induction chemother-
apy could lead to different outcomes of (chemo)radiotherapy,
with good response leading to high rates of locoregional con-
trol by nonsurgical treatment and poor response leading to
low rates of locoregional control. Therefore, induction chemo-
therapy may be used to select patients with resectable
HNSCC for organ preservation by (chemo)radiotherapy. It
has been well-recognized that in patients with laryngeal and
hypopharyngeal cancer who respond to induction chemother-
apy, followed by (chemo)radiotherapy, instead of radical sur-
gery, organ preservation can be achieved without a negative
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impact on overall or disease-free survival.6,9 For other head
and neck tumor sites, there is no conclusive evidence that
induction chemotherapy offers the benefit of organ preserva-
tion.6 Using induction chemotherapy for deintensification of
radiotherapy, particularly in human papillomavirus-associated
oropharyngeal carcinoma, is currently being investigated.13
In order to assess response to induction chemotherapy
without the need for pathological assessment of resected sur-
gical specimen, there is great interest in surrogate metrics for
histopathological response. In other tumors (eg, osteosar-
coma, locally advanced breast cancer, and esophageal can-
cers), which are treated by neoadjuvant chemotherapy and/or
radiotherapy followed by radical surgery, histopathological
examination of the surgical specimen reveals the histologic
response to the neoadjuvant treatment. However, if surgical
resection is not planned, alternative methods of assessment
are needed.
Historically, indices of treatment efficacy in solid tumors
have been based solely on systematic assessment of tumor
size. Changes in tumor size, particularly complete clinical
regression after treatment and the speed of tumor response
are often, but not invariably, related to treatment outcome.14
In contemporary practice, conventional contrast-
enhanced CT and MRI scans provide the mainstay of imag-
ing for treatment response assessment. Both rely on tumor
morphology to evaluate disease, whereas functional imaging,
such as positron emission tomography (PET) and diffusion
weighted (DW)-MRI provide complementary information
about the underlying tumor biology, such as metabolic activ-
ity and cellularity. Changes in tumor metabolism tend to
occur early in the course of therapy and, therefore, precede
reduction in tumor size.
Therefore, functional imaging potentially provides an
earlier indication of response to treatment than conventional
imaging techniques. This not only can act as a prognostic
indicator but, in addition, may allow for adaptation of defini-
tive treatment planning at a time when this is still feasible. In
particular, changes in 18-fluorodeoxyglucose (FDG) uptake
(determined by standardized uptake values [SUVs]) and
microscopic water motion (determined by apparent diffusion
coefficient [ADC]) are potentially useful for assessment of
treatment response. Other techniques include dynamic
contrast-enhanced and perfusion CT and MRI. Optimal tim-
ing and interpretation criteria for use of functional imaging
in daily practice have yet to be developed.
A variety of approaches for measuring response rate
have been developed, including the World Health Organiza-
tion (WHO) criteria (1979),15 the Response Evaluation Crite-
ria in Solid Tumors (RECIST) (2000),16 the RECIST 1.1
(2009),17 the European Organization for Research and Treat-
ment of Cancer (EORTC) criteria for PET (1999),18 the
National Cancer Institute guidelines (2006),19 and the PET
Response Criteria in Solid Tumors (PERCIST) (2009).20
Because of variability in measurements and techniques, clini-
cally useful absolute change values reflecting tumor response
are lacking. These various classifications divide intrinsically
continuous data into bins, losing statistical power in favor of
ease of nomenclature, and convenience in clinical practice.
Rapid assessment of treatment effect may allow clini-
cians to shift patients away from ineffective to effective
therapies at an earlier stage (response-adaptive or risk-
adaptive treatment). Such an approach is an attractive possi-
bility in the drive toward personalized care. Early assessment
of therapeutic efficacy is a key issue in considering the
potential benefit of up-front surgery or of treatment escala-
tion (eg, radiation dose boost) in a nonresponder or avoid-
ance of the unnecessary toxicity and costs of ineffective
treatments. It is important to realize that a complete meta-
bolic response after induction chemotherapy does not always
represent sufficient log cell kill to translate into durable local
control, and cure is then achieved by subsequent definitive
therapy. That said, the frequent observation of pathological
complete responses with chemotherapy alone in HNSCC has
been exploited experimentally in small numbers of very
highly selected patients demonstrating potential for long-
term disease-free survival.21
1.1 | Response assessment in randomized
clinical trials
Randomized clinical trials are considered by many to be the
most reliable form of scientific evidence in the hierarchy of
evidence that influences healthcare policy and practice. This
is because randomized clinical trials help to reduce spurious
causality and bias. Results of randomized clinical trials may
be combined into systematic reviews and meta-analyses,
which are increasingly used in the pursuit of evidence-based
medicine. Recently, a meta-analysis on induction chemother-
apy in patients with resectable HNSCC was performed by
Ma et al.6 From this meta-analysis, all full articles were
selected for review of the response assessment of induction
chemotherapy. Response criteria, technique (physical exami-
nation and/or imaging), and effect of response assessment
are summarized in Table 1.2,9,10,12,22–36 In the majority of
studies, response to induction chemotherapy was assessed by
clinical examination, sometimes combined with CT. How-
ever, the utilization of endoscopy for objective tumor evalua-
tion has not been fully validated.16,37 The majority of studies
used the WHO criteria for response assessment. Unfortu-
nately, in most studies, details of clinical assessment for
tumor regression were not specified.
Some studies show that there is room for improvement in
response assessment in categories that currently include com-
plete regression, partial regression, stable disease, and
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progressive disease. In a study by the Southwest Oncology
Group, the rate of clinical complete response (definition and
diagnostic techniques not reported) was 19%, whereas the rate
of pathological complete response (after induction chemother-
apy, all patients underwent surgery) was 13%, suggesting that
the clinical assessment used at that time (1980-1985) was not
able to detect all residual disease.23
In the final report of the Head and Neck Contracts Pro-
gram,22 in which a single cycle of cisplatin and bleomycin
induction chemotherapy was used, a false-positive rate for
histologic complete response was 82%; of the 22 patients
with clinical complete response, 18 still had microscopic
tumor evident in the surgical specimen. In contrast, 6 of 114
patients (5%) with clinical partial responses had no evidence
of cancer in the resected primary tumor.22 The EORTC study
(1978-1984) in 97 patients with oral and oropharyngeal can-
cer also noted a discrepancy between clinical and histopatho-
logical regression after induction chemotherapy. Of the 6
patients with clinical complete regression, only 4 patients had
pathological complete regression. Of the 46 patients with
50% or more clinical regression, only 31 patients (67%) had a
pathological regression, defined as disappearance of living
tumor cells (complete response) or persistence of islets of liv-
ing tumor cells (partial response). Finally, of 48 patients with
clinical regression of <50%, 3 patients (6%) were found to
have a pathological complete regression.25
Maipang et al28 reported that in 3 of the 9 patients (33%)
with clinical or radiological complete response after 2
courses of induction chemotherapy, tumor was still detected
histologically.28 In the Veterans Affairs study (started in
1985) on advanced laryngeal cancer, a difference in clinical
and pathological assessment results were found; pathologi-
cally confirmed complete regression was found in 88% of
the patients with clinical complete response and 45% of those
with partial response.8
In a study by Zhong et al,38 222 patients with advanced
stage oral squamous cell carcinoma were randomized
between induction chemotherapy (2 cycles of docetaxel, cis-
platin, and 5-fluorouracil) followed by radical surgery and
postoperative radiotherapy (range 54-66 Gy) versus up-front
radical surgery and postoperative radiotherapy. Of 124
patients who received induction chemotherapy, 8.1% were
considered to have had a clinical complete response but
13.4% achieved a pathologic complete response. Clinical
tumor response was determined by clinical evaluation and
imaging studies (performed at baseline and 2 weeks after
cycle 2 of induction chemotherapy). The imaging studies
were not further specified. Responses were characterized
according to the RECIST criteria.38
The reported findings suggest room for improvement in
response assessment after induction chemotherapy, but an
optimal method has yet to be identified.
1.2 | Morphological response assessment
Imaging at baseline and after 1 or 2 cycles of (induction)
chemotherapy can be performed to estimate whether the
treatment is effective in that specific tumor and patient.
Contrast-enhanced CT and MRI provide the mainstay of
imaging for response assessment in head and neck cancer.
The proposed methods to assess treatment response by the
WHO criteria include determining the bidimensional meas-
urements of tumors, whereas for RECIST/RECIST 1.1 only
unidimensional measurements are used.16,17 According to
the WHO criteria, for a clinically complete response, no
tumor is visible, and for a partial response, tumor is visible
but a reduction of >50% of the product of 2 perpendicular
diameters is observed, which is confirmed after an interval of
at least 4 weeks.15 The major reference for justifying a 50%
decrease as a criterion for tumor response was based on an
experiment in which experienced oncologists had to assess
solid wooden spheres placed on a soft mattress and covered
with a layer of rubber foam by palpation. Because of measure-
ment errors, the assessed sizes of identical spheres differed by
at least 25% in 25% of the measurements and by at least 50%
in only 6.8% of the measurements, which was considered
acceptable. Thus, if a reduction of 25% in the product of the
perpendicular diameters of the “tumors” was considered a
response, an unacceptable high false tumor reduction occurred
25% of the time. However, when a 50% threshold was applied,
the error fell to an acceptable 7% false-positive rate.39,40
The RECIST criteria, developed by the National Cancer
Institute and the EORTC, define response as a 30% decrease in
the largest diameter of the tumor. For a spherical lesion, this
measure is equivalent to a 50% decrease in the product of 2
diameters (as used in the WHO criteria). Using the RECIST cri-
teria, changes (for at least 4 weeks) are categorized as complete
response, partial response, stable disease, or progressive disease.
Measurable lesions (used for assessment of response) are
defined based on longest diameters, because in smaller lesions
the risk of changes by chance is higher. A good concordance
was found between response assessment using the RECIST and
the WHO criteria for the 4 bins of response in the same patients
recruited in 14 different trials. The most precise estimates are
achieved when the same imaging technique is used and the
same reader assesses the baseline and follow-up evaluations;
more misclassifications and variance in response are noted with
different readers. Tumor size is clearly an important parame-
ter.16 Due to the irregular 3D shapes of many head and neck
tumors, particularly for the oral cavity, the maxilla, and the lar-
ynx, the RECIST criteria may not be sensitive for predicting
response after chemotherapy, as found by Patil et al41 in a small
study showing a low correlation between the RECIST response
and response on pathological examination.
Traditionally, the morphologic response to therapy has
been performed with 2D measurements of size. Advances in
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CT and MRI techniques and software technology have led to
considerable refinements in the accuracy of tumor size meas-
urements facilitating tumor volume measurements. Baghi
et al42 found a significant difference in tumor volume before
and after 3 cycles of induction chemotherapy (docetaxel, cis-
platin, and 5-fluorouracil) in 50 patients with HNSCC. In 78
patients with laryngeal cancer treated with definitive radia-
tion, Issa et al43 found that CT scans estimated pretreatment
tumor volumes (both primary tumor and composite volumes
including nodes) were highly prognostic of success, but that
this prognostic value was absent after a single cycle of induc-
tion chemotherapy, suggesting that tumor volume assessment
after induction chemotherapy is not of prognostic signifi-
cance. However, further research on the values of volume
measurements for clinical response evaluations is warranted.
For clinical trials, morphological measurements according to
the RECIST 1.1 are recommended (Table 2).17
Morphologic measurements are most often used, but
have limited value in response assessment after induction
chemotherapy to individualize further treatment.
1.3 | Functional response assessment
Conventional CT and MRI scans rely on morphology to evalu-
ate disease. In contrast, functional imaging, such as PET, DW
MRI, dynamic contrast-enhanced (DCE) MRI, and other
advanced functional imaging techniques provide complemen-
tary information on the underlying biology. This information
includes metabolic activity, cellularity, vascularity, and oxy-
genation, all of which are potential mediators of chemotherapy
and radiation resistance. The reduction in metabolic signal, as
depicted on functional imaging, can significantly exceed reduc-
tions in morphological volume as defined on CT or MRI.44 A
minimum of 10 days delay between a chemotherapy cycle and
FDG-PET scanning permits bypassing of the chemotherapeutic
effect and transient fluctuations of FDG-PET that may occur
early after treatment (stunting or flare of tumor uptake). This
“metabolic flare” is a transient increase in FDG uptake and is
thought to consist of 2 effects: an increased metabolism due to
cellular stress and an influx of FDG due to damaged cellular
membranes.45
In several small studies, early therapeutic response on
FDG-PET and DW-MRI after 2 cycles of induction chemo-
therapy in patients with advanced-stage HNSCC seems to be
a predictive factor for recurrence-free survival after subse-
quent chemoradiation.46
1.4 | Fluorodeoxyglucose-positron emission
tomography
Although a range of factors have been associated with 18F-
FDG uptake, there seems to be a rather strong relationship
between FDG uptake and cancer cell number. Therefore, it is
reasonable to expect that decreases in tumor FDG uptake
would be seen with a loss of viable cancer cells.
Although a completely negative PET scan at the end of
therapy typically suggests a good prognosis, it does not nec-
essarily correspond to a complete absence of cancer cells, as
FDG-PET is unable to discriminate between minimal tumor
burden and no tumor burden. Because FDG uptake is usually
not absent in patients who respond well to treatment, prog-
nostic stratification between high and low FDG uptake after
or during treatment using absolute cutoff values or cutoff
thresholds for percentage decline have been advocated.
Metabolic activity and changes due to treatment can be
assessed in various ways: qualitative or quantitative; binary
(yes or no response); classified (several groups) or continu-
ous (giving varying degrees of response); in the most meta-
bolic active region or the entire tumor volume; in only the
primary tumor, the maximal number of lesions or all lesions;
and from the same lesion or the most intense lesion (not nec-
essarily the same as the most intense lesion on the other
scan).
For early (subtle) changes in tumor uptake before the
ultimate treatment effect is complete, quantification may be
more desirable than qualitative scoring. Response does likely
represent a continuum of intensities of uptake. Because PET
is intrinsically a quantitative imaging method, quantitative
measurement of early treatment-induced changes is an attrac-
tive tool for measuring subclinical response and more com-
plete changes. More than 30 different ways to assess tumor
response by PET quantitatively have been reported, but
SUVs are the most widely applied, generally correlating well
with more complex analytic approaches. The SUV is a
TABLE 2 Response Evaluation Criteria in Solid Tumors criteria
RECIST 1.1
Target lesion
Measurable lesions Longest diameter of tumors or metastasis
1.0 cm
Short axis of lymph node metastasis 1.0
cm
Nonmeasurable Longest diameter <10 mm or pathological
lymph nodes with 10 to <15 mm short
axis)
Leptomeningeal disease, ascites, pleural or
pericardial effusion, inflammatory breast
disease, lymphangitic involvement of skin
or lung, bone metastasis without soft tissue
component
Measurements Up to 5 lesions, with a maximum of 2
lesions per organ
Abbreviation: RECIST, Response Evaluation Criteria in Solid Tumors.
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widely used metric for assessing tissue accumulation of trac-
ers. The SUV can be normalized to total body mass, lean
body mass, or body surface area. Although these SUV nor-
malization approaches will give different absolute change in
SUVs with effective treatment and different absolute amount
of change to be significantly different from a previous scan,
the percentage changes with treatment will be comparable in
a single patient with a stable weight and identical patient
preparation and scan protocol.20
A wide variety of region of interest (ROI) selection met-
rics has been used: manually defined ROI (tumor delinea-
tion), isocontour ROIs based on a fixed percentage of the
maximal pixel in tumor, fixed SUV threshold, or a
background-level threshold and fixed dimension. The most
frequently used SUV metric is the SUV obtained from the
pixel with the highest uptake within the tumor (SUVmax).
Another SUV metric is standardized uptake value peak
(SUVpeak), which is defined as the average SUV within a
small, fixed-size ROI (a 1 cm3 volume spheric ROI) centered
on a high-uptake part of the tumor.20
The SUV reproducibility, which is important in clinical
practice, is mainly dependent on the ROI and lesion size.
Small lesions may have low uptake of FDG due to partial
volume effect. The SUVmax can easily be measured using
modern commercial workstations and is most resistant to par-
tial volume effect in small tumors, but is highly dependent
on the pixel size. The SUVpeak in a small volume of greatest
metabolic activity in the tumor is less subject to variance
than is a small, single pixel SUVmax. Because SUVs of
small lesions are more susceptible to measurement faults,
tumor sizes should be noted and should be 2 cm or larger in
diameter for accurate measurement, although smaller lesions
of sufficient FDG uptake, including those not well seen ana-
tomically, can be assessed. Generally, lesions must be clearly
visible and both large enough and hot enough to evaluate
changes in SUV.20 Standardization, as proposed in the
United States19 and Europe,36 is essential to achieve repro-
ducible SUVs.
A variety of methods has been used to determine the
change in SUVs associated with treatment. Absolute SUV and
percentage decline in SUV can both be used to assess treat-
ment response. The ratio of SUV is less dependent on ROI
choice than absolute SUV determinations and is, therefore,
preferred.47 Moreover, using absolute SUV decline in multi-
center studies and comparing between reported studies may be
difficult due to inadequate standardization of SUV determina-
tion. An SUV decline of 30%-35% is usually associated with
a good outcome. However, the decline warranted for achieve-
ment of treatment goal may be dependent on tumor type, treat-
ment performed, and time interval after treatment.47
In patients with multiple lesions, several strategies to
assess response to therapy by SUV decline have been
described: (1) assessment of SUVmax (the single, most
intense area in the primary tumor (not necessarily the same
area), which is considered to coincide with the worst-case
biologic behavior of malignancy) decline of the primary
tumor only, because changes in SUV of the primary tumor
seem to predict the outcomes in metastases quite accurately;
and (2) the smallest percentage decline in SUVpeak of a
lesion as representative, with the rationale that the lesion
with the worst response would determine survival.20
The medically relevant cutoff value for an SUV decline
to optimally represent response and predict outcome may dif-
fer on the basis of disease, the timing after treatment, the
treatment itself, and the treatment goal. Early during treat-
ment, lower cutoff values may be used than following com-
pletion of treatment. In addition, for induction
chemotherapy, this cutoff value may be lower as further
treatment is foreseen. This cutoff value can be used for
response-adaptive treatment (eg, concurrent [chemo]radio-
therapy with eventual additional cycles of induction chemo-
therapy for responders or surgery with or without
postoperative radiotherapy in nonresponders). Decisions to
deny probably ineffective therapy depend on alternative ther-
apeutic options available and on the risk, costs, and per-
ceived benefits of available treatment options. In the case of
false-positive findings, when induction chemotherapy is fol-
lowed by radiotherapy instead of defaulting to surgical resec-
tion, tumor relapse is more likely to occur. This may then
require salvage surgery with a higher risk of postoperative
complications. With regard to predicting further response to
subsequent radiotherapy, it is not always essential to achieve
histopathological complete response after induction
chemotherapy.
The delay in translating PET as response metric from
research to clinical practice is probably due to the variability
in study performance (imaging protocol) and the lack of uni-
formly practiced response metrics for PET. Standardized
approaches to the performance of PET and to machine cali-
brations have been articulated.19,47 Qualitative and quantita-
tive approaches for PET treatment response assessment have
been postulated.16,20
In the RECIST 1.1, FDG-PET scanning may only be
incorporated to complement CT scanning in assessment of
progression.17 The only exception to this is in the use of
FDG-PET imaging as an adjunct to determination of progres-
sion, as described later in this guideline. Recently, Hyun
et al48 reported on a simplified guide to PERCIST 1.0, which
describes in detail methods for controlling the quality of
FDG-PET imaging conditions to ensure the comparability of
PET images from different time points to allow quantitative
expression of changes in PET measurements for an assess-
ment of overall treatment response in PET studies. The PER-
CIST uses the SUVpeak corrected for lean body mass
2338 | DE BREE ET AL.
(SULpeak) and defines criteria for measurable lesions. In
short, responses are categorized in: (1) complete metabolic
response: complete resolution of FDG uptake; (2) partial
metabolic response: a decrease of 30% and of at least 0.8
SUL units between the most intense evaluable lesion at base-
line and follow-up (not necessarily the same lesion); (3) sta-
ble disease: an increase or decrease in SULpeak of <30%;
(4) progressive disease: an increase 30% and an increase of
at least 0.8 SUL units in target lesion or development of a
new lesion (Table 3).20,48 For functional response assessment
using FDG-PET in clinical trials, the PERCIST criteria are
recommended.
1.5 | Clinical studies
Dalsaso et al49 performed CT and FDG-PET before and after 2
or 3 cycles of paclitaxel and carboplatin in 19 patients with
advanced head and neck cancer. A suboptimal reference stand-
ard was used: 4 biopsies from 4 separate sites within the tat-
tooed primary tumor area before treatment. A significant
difference in mean reduction of SUVmean was found in com-
plete pathologic responders, defined as patients with negative
biopsies after chemotherapy (82%) as compared with patients
having residual disease (35%). Although no significant differ-
ence in mean reduction in tumor volume by CT between these
patient groups was observed, a significant correlation between
percent reduction of SUVmean and percentage reduction in
CT tumor volume after chemotherapy was found.49
In patients with locally advanced HNSCC, Brun et al50
found that patients who had an SUVpeak of FDG lower than
the median value after 1 cycle of chemotherapy or 12-40 Gy
radiotherapy have a higher tumor response and better sur-
vival as compared to those with a higher than median SUV-
peak. Unfortunately, patients who underwent FDG-PET after
induction chemotherapy were not separately evaluated.50
McCollum et al51 analyzed the FDG-PET results of 26
patients with advanced-stage head and neck cancer after 3
cycles of induction chemotherapy with cisplatin and 5-
fluorouracil with or without docetaxel. When the outcome of
histopathological examination of a biopsy from the primary
tumor site was used as reference standard, a high sensitivity
(100%) and negative predictive value (100%) but a low spec-
ificity (65%) and positive predictive value (27%) were found
for detecting persistent disease at the primary site. However,
the possibility of false-negative results from biopsy specimen
sampling errors could not be ruled out.51
The FDG-PET and CT were compared with endoscopy
and biopsy while the patients were under general anesthesia
3 weeks after a single course of induction chemotherapy
with cisplatin or carboplatin and 5-fluorouracil in 12 patients
with resectable advanced-stage oropharyngeal cancer by
Chepeha et al.37 During endoscopy with the patients under
general anesthesia after induction chemotherapy, the percent
of residual primary tumor was estimated by the surgeons rel-
ative to the tattoo markings made during the pretreatment
endoscopy. Endoscopy was used as reference standard and
TABLE 3 Positron Emission Tomography Response Criteria in
Solid Tumors criteria
PERCIST 1.0
Target lesion requirements
and selection at baseline
SUVpeak measurement of the hottest
lesion (known areas of iatrogenic or
benign uptake should not be selected
[eg, Waldeyers ring], even when
such a lesion has the highest
SUVpeak)
SUVpeak 1.5 times SUVmean liver
1 2 SD SUVmean liver
In case of extensive liver metastases,
SUVpeak 2.0 times SUVmean
aorta 1 2 SD SUVmean aorta
It should be reported when no target
lesion can be selected because they
are below the minimum threshold
Follow-up lesion selection SUVpeak measurement of the hottest
lesion (may not be the hottest tumor at
baseline)
Response measurement
and reporting
Reporting of percentage of change in
tumor metabolism with notation of
number of weeks since treatment start
5 100 3 [SUVpeak follow-up target
lesion – SUVpeak baseline target lesion]
/ SUVpeak baseline target lesion
Response categories
Complete metabolic
response
Partial metabolic
response
Stable metabolic disease
Progressive metabolic
disease
SUVpeak < SUVmean liver and
indistinguishable from surrounding
background
30% decrease of SUVpeak follow-
up target lesion and:
- At least 0.8 SUV units decrease
of SUVpeak follow-up target
lesion compared to baseline
- No new FDG-avid lesions in a
pattern typical of cancer
- No increase in size > 30% of
target lesion
- No increase in size or SUVpeak
of >30% in nontarget lesion
Increase or decrease of SUVpeak
follow-up lesion <30%
Increase of SUVpeak >30% and at
least 0.8 SUV units
New FDG-avid lesion(s) in a typical
pattern of metastasis
Abbreviations: FDG, fluorodeoxyglucose; SUV, standardized uptake value; SUV-
mean, standardized uptake value mean; SUVpeak, standardized uptake value peak.
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to decide whether to continue with nonsurgical treatment
(concomitant chemoradiation followed by adjuvant chemo-
therapy if response is at least 50%) or subsequent surgery
with postoperative radiotherapy (if response is lower than
50%). Although SUVmax values were determined for each
tumor, these SUVs were only used as addition to visual esti-
mation of response and not for calculation of SUVmax
change. Tumor volumes were assessed on CT. The agree-
ment between PET and endoscopy was substantial and the
agreement between CT and endoscopy was fair. They sug-
gest that FDG-PET is more reliable than CT for predicting
tumor response, although the reference standard was not
ideal. The authors hypothesize that FDG-PET can replace
endoscopy with biopsies for assessment of tumor response
after induction chemotherapy.37
Argiris et al52 reported on a series of 39 patients with
locally advanced head and neck cancer who underwent
induction docetaxel, cisplatin, and cetuximab followed by
concurrent radiotherapy, cisplatin, and cetuximab and
maintenance cetuximab. Response assessment was per-
formed after 3 cycles of this induction protocol by CT,
physical examination, and the FDG-PET portion of PET/
CT. Complete response by PET was defined as complete
disappearance of FDG activity attributable to malignancy,
without regard to the degree of CT response, as assessed
on combined PET/CT. Substantial differences in complete
response rate as assessed by CT, physical examination, and
PET were reported: for primary tumor 48%, 70%, and 58%,
and for lymph node metastases 5%, 34%, and 21%,
respectively.52
Kikuchi et al53 evaluated the predictive value of sequential
FDG-PET/CT after 1 cycle of neoadjuvant chemotherapy (the
platinum complex CDGP and the oral fluoropyrimidine deri-
vate S-1) in 16 patients with HNSCC. They used the SUVmax
of 15 primary tumors and 11 (largest) lymph nodes and grad-
ing of histopathological regression as the reference standard
(response: <10% vital tumor in tumor bed; nonresponse 10%
or more vital tumor in tumor bed). Although 2 different PET/
CT scanners were used, sequential PET/CT scans before and
after induction chemotherapy were performed using the same
protocol and scanner for each patient. Postchemotherapy SUV-
max (cutoff point 3.5) and percentage decline in SUVmax (cut-
off point 55.5%) were shown to predict histopathological
responses with a sensitivity of 71% and 86%, a specificity of
89% and 95%, a positive predictive value of 71% and 86%,
and a negative predictive value of 89% and 95%, respectively.
The MRI findings based on longest diameter before and after
chemotherapy were not able to predict histopathological
response in these same patients.53 In a later study, Kikuchi
et al54 used the same SUVmax decrease threshold of 55.5% for
defining responders and nonresponders to induction chemo-
therapy by FDG-PET/CT evaluation in comparison to the
RECIST with MRI evaluation. Only nonresponders revealed
by FDG-PET/CT were significantly linked to poor local tumor
control rate and disease-specific survival (hazard ratio 4.9).54
Yoon et al55 evaluated the efficacy of FDG-PET after 2
cycles of induction chemotherapy (S-1 and cisplatin) in 21
patients with advanced-stage head and neck cancer who
achieved partial response to predict clinical outcome after
concurrent chemoradiation. Patients who attained a complete
response (according to RECIST) after concurrent chemora-
diation showed a significantly higher decrease in SUVmax
compared with patients who failed to attain a complete
response. An SUVmax of at least 4.8 on FDG-PET after
induction chemotherapy and a decrease from baseline of at
least 65% in SUVmax after induction chemotherapy pre-
dicted complete response after concurrent chemoradiation
and progression-free and overall survival.55
The potential of FDG-PET/CT after 2 (or 3) cycles of
docetaxel, cisplatin, and 5-fluorouracil to predict disease-free
survival in 15 patients with locally advanced HNSCC treated
by induction chemotherapy preceding concomitant chemora-
diation was evaluated by Abgral et al.46 Metabolic response
was assessed by the measurement criteria of the EORTC.
The 1-year disease-free survival of metabolic responders,
defined as at least 25% decrease (between baseline and after
2 cycles of induction chemotherapy) of SUVmax, was statis-
tically significantly better than nonresponders (100% vs
20%; P 5 .0014).46
A greater reduction in FDG-avid volume and, hence,
metabolic signal than in reduction of volume on conventional
imaging (CT and MRI) after induction chemotherapy was
observed by Powell et al.44
The FDG volumetric imaging parameters to assess
response to induction chemotherapy were used by Yu et al56
in 28 patients with advanced-stage HNSCC who underwent
3 cycles of TPF chemotherapy (docetaxel, cisplatin, and 5-
fluorouracil) followed by chemoradiation. Different parame-
ters for metabolic tumor volume and total lesion glycolysis
were evaluated. A reduction of 42% of metabolic tumor vol-
ume and 55% of total lesion glycolysis were predictive of
progression-free survival after subsequent chemoradiation
with a sensitivity of 67% and 63% and a specificity of 90%
and 90%, respectively.56
In a preliminary study, Gavid et al57 assessed the correla-
tion between reduction in SUVmax and in metabolic tumor
volume (measured from isocontours of SUV 5 2.5) after a
first cycle of induction TPF chemotherapy (docetaxel, cispla-
tin, and 5-fluorouracil) and clinical response, as assessed by
endoscopy with taking of biopsies after 2 or 3 cycles of
induction chemotherapy in 21 patients with advanced-stage
HNSCC. Using this suboptimal reference standard, patients
with advanced-stage HNSCC with 70% tumor reduction on
endoscopy and negative biopsies were considered to be
responders and continued with chemoradiation, whereas
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nonresponders underwent surgery. Responders showed a sig-
nificantly greater mean SUVmax reduction between PET/CT
examinations pretreatment and after 1 cycle of chemotherapy.
Responders tended to show greater reduction in hypermeta-
bolic volume than nonresponders.57
Semrau et al58 performed response assessment using
FDG-PET/CT and endoscopic evaluation after a single cycle
of induction chemotherapy using docetaxel and cisplatin or
carboplatin in 47 patients with advanced-stage HNSCC.
Responders achieving a 30% decrease in endoscopic tumor
size and a 20% decrease in SUVmax proceeded to chemo-
radiation and nonresponders to surgery. In 89% of these
patients, metabolic and clinical responses were similar. Using
this strategy of selecting patients for chemoradiation or sur-
gery, a local control rate of 86% was obtained.58
Assessment by PET/CT and DW-MRI after the first
cycle of induction chemotherapy (docetaxel, cisplatin, and 5-
fluorouracil) in 20 patients with advanced-stage HNSCC
who received 2 cycles of induction chemotherapy followed
by concomitant chemoradiation was reported by Wong
et al.59 Responders, defined as patients without persistent
disease at response assessment at 3 months after completion
of chemoradiation with MRI, PET/CT, and clinical examina-
tion, showed a significantly greater reduction in metabolic
tumor volume and total glycolysis both measured for ROI
with uptake of 40% of SUVmax and with SUV 3.5.59
Recently, a systematic review on the effectiveness of
FDG-PET/CT for evaluating early response to induction
chemotherapy in HNSCC was performed. Seven studies
including a total of 207 patients with advanced-stage HNSCC
were included. The authors concluded that a meta-analysis
was not possible because the selected studies were heterogene-
ous concerning response criteria, reference standards, chemo-
therapy strategy, and endpoints. However, 6 of 7 studies
concluded that FDG-PET allowed early evaluation response
to induction chemotherapy and predicted survival outcomes.60
The studies cited above demonstrate the potential of
FDG-PET to assess response to induction chemotherapy in
order to select patients for treatment adaptation (ie, concomi-
tant chemoradiation or surgery). Unfortunately, different
parameters have been used for response assessment. More-
over, SUV cutoffs identified in (single center) studies involv-
ing a specific set of patients may not be applicable to other
centers with different equipment, patient populations, chemo-
therapy regimens, and clinical imaging protocols. Reporting
the SUV changes as figures and not only as the PERCIST
criteria would be helpful to assess the most useful cutoff
value, as otherwise the advantages of the continuous output
of PET data are lost through forced categorization.
If induction chemotherapy is used to select patients with
resectable HNSCC for organ preservation by (chemo)radio-
therapy, response assessment would preferably be performed
after only 1 cycle in order to avoid further unnecessary treat-
ment with its associated burden, toxicity, and morbidity. In
Table 4, studies using FDG-PET for response assessment after
induction chemotherapy are ordered according to the timing
of the assessment. Unfortunately, due to aforementioned heter-
ogeneity, only the conclusion can be made that even after one
cycle FDG-PET is very promising for this purpose.
2 | MORE RECENT ADVANCES IN
IMAGING
2.1 | Diffusion-weighted MRI
Diffusion-weighted DW-MRI, which provides maps of
microscopic water motion within biologic tissues, offers a
simplistic approach (as compared to CT perfusion and DCE-
MRI) to physiologic changes within the tumor after treat-
ment. Higher cellularity (eg, malignant tumor) is generally
associated with more restricted diffusion (lower ADC
values).
Because ADC measurements are dependent on a high
number of adjustments, which differ between scanners and
protocols, results from studies are not generally applicable
across different institutes, hampering its implementation.61
Changes in ADC values are probably less dependent on
DW-MRI scanners and protocols than absolute ADC
values.
Cytotoxic therapy triggers tumor cell death, leading to
reduced density with a subsequent increase in ADC after treat-
ment. Berrak et al62 evaluated the potential of DW-MRI in
monitoring the treatment response of the largest metastatic cer-
vical lymph node in patients with HNSCC undergoing
cisplatin-based induction chemotherapy. Each patient underwent
an MRI on the same 2 scanners used. Changes in nodal volume,
signal intensity on T2, and ADC were not different for complete
and partial responders at different clinical endpoints. Although
no difference in changes in nodal volume and signal intensity
on T2 were found between survivors and those who died of
HNSCC, a significant difference in percentage change in ADC
between those patient groups was observed.62 In the previously
mentioned study of Wong et al,59 a trend was observed for a
higher ADC on DW-MRI after 1 cycle of induction chemother-
apy in responders compared with nonresponders of induction
chemotherapy followed by concomitant chemoradiation.59
Conventional DW-MRI cannot separate perfusion and
true diffusion-related effect. Intravoxel incoherent motion
(IVIM) imaging is characterized by 3 parameters: pure diffu-
sion coefficient; microvascular volume fraction; and
perfusion-related incoherent microcirculation. The IVIM-
derived parameters may characterize the actual status of dif-
fusion in tumors more accurately then conventional DW
because it provides both perfusion and true diffusion-related
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measurements. In a recent study by Guo et al,63 IVIM meas-
urements were performed before and after 2 cycles of pacli-
taxel and cisplatin induction chemotherapy in 28 patients
with advanced-stage hypopharyngeal carcinoma. Response
was classified according to RECIST 3 weeks after the second
cycle of induction chemotherapy by conventional MRI. The
posttreatment ADC and pure diffusion coefficient were sig-
nificantly higher in responders than in nonresponders,
whereas perfusion-related incoherent microcirculation was
significantly lower in responders and microvascular volume
fraction was not significantly different. Changes (between
pretreatment and 3 weeks after induction chemotherapy) of
ADC, pure diffusion coefficient, and perfusion-related inco-
herent microcirculation were significantly higher in
responders, but microvascular volume fraction was not.63
The DW-MRI is a promising technique for response
assessment, but further research using a standardized proto-
col is needed for eventual implementation in clinical
practice.
2.2 | CT and MRI perfusion
A number of methods have been developed for the measure-
ments of tissue perfusion using CT and MRI. These methods
can generally be grouped under 2 classes: compartmental
analysis and deconvolution-based methods. Perfusion studies
are obtained by monitoring a standard iodinated contrast of
gadolinium bolus through a vascular bed.
Deconvolution-based CT perfusion is a fast imaging
technique, which can assess physiologic parameters, such as
blood flow, blood volume, mean transit time, and capillary
permeability surface area product, and provides data that can
be useful in the detection and characterization of tumor. Sig-
nificant perfusion differences of blood flow, blood volume,
mean transit time, and capillary permeability have been
found in untreated HNSCC compared with adjacent normal
tissue.64 CT perfusion has been proposed as a new, possibly
superior evaluation of tumor response. After intravenous
injection of a bolus iodinated contrast agent, tissue and ves-
sel attenuation changes can be observed during the first pass
of the agent by dynamic image acquisition at a given ana-
tomic level. Time-density curves can be constructed for
observer-defined ROI. Within limits of assumptions, tissue
perfusion can be estimated based on observed density
changes. The time course of the iodine concentration is a
measure of the regional perfusion, and this concentration is
linearly correlated to tissue density, as seen on CT. Several
algorithms can be used to measure perfusion with CT. Gan-
dhi et al65 examined whether these CT perfusion parameters
correlate with response to induction chemotherapy as
assessed by endoscopy with the patient under general anes-
thesia. In 9 patients with advanced head and neck cancer,
reduction in blood volume by >20% on CT perfusion 3
weeks after 1 cycle of induction chemotherapy (cisplatin and
5-fluorouracil) showed substantial agreement with clinical
response (50% reduction in tumor volume), as assessed
with endoscopy. The agreement among decreased (20%)
blood flow, decreased (20%) capillary permeability, and
increased (20%) mean transit time and clinical response
was fair. Based on these results, the authors hypothesized
that CT perfusion parameters could potentially replace inva-
sive diagnostic procedures with the patient under general
anesthesia as a predictor of tumor response.65
Petralia et al66 found a correlation between a decrease in
both blood flow and blood volume on perfusion CT and
tumor volume reduction in 20 patients with advanced-stage
head and neck cancer after 2 cycles of cisplatin and 5-
fluorouracil as induction chemotherapy.
In DCE-MRI, several parameters can be computed pixel-
wise: transfer constant (Ktrans), the volume of extravascular
extracellular space per unit volume of tissue (Ve), the initial
(60s) area under the gadolinium curve (IAUGC60) and the
enhancing fraction. Powell et al.44 reported a significant fall of
the transfer constant Ktrans and IAUGC60 after chemotherapy.
These advanced perfusion imaging techniques for
response assessment are still in an exploratory phase and not
ready for use in clinical practice.
2.3 | Future development of response
assessment
The clinical utility of imaging after induction chemotherapy
but before subsequent locoregional therapy is based on the
ability to predict clinical response and survival after sequen-
tial definitive therapy (ie, concurrent [chemo]radiation or
surgery). It is not always essential to achieve complete
response after induction chemotherapy, because subsequent
definitive (chemo)radiation may eradicate residual disease.
Rough classification systems for tumor response have been
used for decades because precise techniques were not or
later not yet widely available. However, more recent mor-
phological and functional imaging techniques may allow for
more reliable reporting on changes during or after treatment.
Therefore, individual figures can be used in reporting
response assessment and categories can be made based on
optimal cutoff values. Because new treatment paradigms
and new imaging modalities and techniques require contin-
ued reevaluation of response assessment tools, recently, the
RECIST working group proposed organ-specific modifica-
tions. However, these are not yet defined for head and neck
cancer.67
Although the WHO and the RECIST criteria are histori-
cally focused on a reliable assessment of any response after
induction chemotherapy, new quantitative functional imaging
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techniques will determine a cutoff value for optimal prediction
of response after subsequent chemoradiation. These cutoff val-
ues will be dependent on alternative treatment options, avail-
able treatment modifications, and the opinions of patients and
their clinicians. However, when new techniques are evaluated
for their potential role in determination of response to induction
chemotherapy, an initial correlation between imaging parame-
ters and response have to be investigated.
Several studies suggest that functional imaging techni-
ques show potential in determining response to induction
chemotherapy when compared to morphological radiological
or clinical assessments. However, the wide variety of
methodologies and endpoints reported limit the conclusions
that can be drawn at this stage. Nevertheless, functional
imaging holds promise for more personalized treatment using
induction chemotherapy to select patients with HNSCC for
definitive therapy.
2.4 | Use of biomarkers for response
assessment
A major goal of response assessment to induction chemo-
therapy is proper selection of patients for subsequent man-
agement based on the biologic response of the tumor to
initial cytotoxic chemotherapy in anticipation of improved
survival and/or organ preservation. However, if surrogate
biomarkers could predict the response to chemotherapy,
treatment selection for definitive therapy could be
improved, toxicities reduced, redundant treatment avoided,
and perhaps other biologic methods to monitor response
could be developed that would guide changes in ther-
apy.68,69 In general, it seems consistent that tumor or
molecular characteristics that reflect rapid tumor growth or
high cellular proliferation tend to correlate with responses
to induction chemotherapy, whereas lack of aggressive
growth, proliferation, or invasiveness tend to predict better
responses to surgical excision.
2.5 | Response assessment after induction
immunotherapy
Although the focus of this review is response assessment after
induction chemotherapy, the immunotherapy of head and neck
cancer is the most rapidly developing frontier of treatment and
has been stimulated by the approval of several immune check-
point inhibitors for clinical use in patients with advanced can-
cers.70,71 Further, induction immune modulation is gaining
increasing popularity as a means to assess the clinical and
immunologic effectiveness of these agents.72 Like the develop-
ment of induction chemotherapy approaches, methods to pre-
dict and appropriately assess tumor and immunologic
responses after induction immune modulation are needed.
However, it is unclear if the clinical or radiologic measures
that have been proven useful after induction chemotherapy will
be equally useful after immunotherapy because effects of
immune-mediated cytotoxicity tend to evolve more slowly
than direct cytotoxic agents and may be accompanied by initial
tumor swelling, acute inflammation, or increased functional
activity due to influx of tumor-infiltrating lymphocytes. Appro-
priate metabolic imaging will likely be more meaningful than
anatomic imaging. Considerable effort is underway to define
both molecular and immune markers that predict success of
immune modulation with the checkpoint inhibitors. Clearly,
what has been learned regarding the monitoring of tumor
response to induction chemotherapy could have important
implications for the development of induction immunotherapy
regimens for patients with head and neck cancers. Patients
with head and neck cancers will continue to represent an ideal
model for future development of induction chemotherapy and
immune therapy regimens and associated biomarkers to guide
selection of appropriate definitive treatment modalities for
more personalized care.
3 | CONCLUSION
Induction chemotherapy may be used to tailor the treatment
plan to the individual patient with head and neck cancer:
following the planned subsequent (chemo)radiation sched-
ule, planning a radiation dose boost, or reassessing the
modality of treatment (ie, up-front surgery). For this pur-
pose, reliable response assessment is needed. Response
assessment after induction chemotherapy is currently prob-
ably most valuable if a choice between an organ-
preservation approach (radiotherapy with or without chem-
otherapy) and surgery has to be made, particularly for
hypopharyngeal and laryngeal cancer. Response assessment
using conventional clinical morphological techniques is
limited. Functional imaging, in particular using FDG-PET,
is promising, but the introduction in routine clinical practice
is limited due to the variability in study performance (imag-
ing protocol) and the lack of uniformly practiced response
metrics for PET. Research on other functional imaging
techniques for response assessment is scarce and these tech-
niques are still in an exploratory phase. Surrogate bio-
markers, which predict the response to chemotherapy and
may be used to select definitive therapy with less toxicity,
are under investigation. To allow comparison of clinical
trial results and development of guidelines for the use of
induction chemotherapy, it is essential that for response
assessment radiological measurements are performed
according to current guidelines using the RECIST 1.1 (if
only morphological imaging is performed) and the PER-
CIST 1.0 criteria on accredited PET/CT scanners. Whereas
the RECIST criteria are historically focused on a reliable
2346 | DE BREE ET AL.
assessment of any response after induction chemotherapy,
new quantitative (functional imaging) techniques will
attempt to predict response after subsequent chemoradiation
using cutoff values. Optimal cutoff values can only be
determined if trial results are reported as continuous data
and not only in categories of response.
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